Jason P Sheehan, MD – University of Virginia discusses the Focused Ultrasound Shows Potential Against Deadliest Brain Tumor https://news.virginia.edu/content/focused-ultrasound-shows-potential-against-deadliest-brain-tumor
Author: Editor
Jason P Sheehan, MD – University of Virginia discusses the Focused Ultrasound Shows Potential Against Deadliest Brain Tumor https://news.virginia.edu/content/focused-ultrasound-shows-potential-against-deadliest-brain-tumor
Jason P Sheehan, MD – University of Virginia discusses the Focused Ultrasound Shows Potential Against Deadliest Brain Tumor https://news.virginia.edu/content/focused-ultrasound-shows-potential-against-deadliest-brain-tumor
Debra L. Richardson, MD – Sarah Cannon discusses Phase I expansion study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC): Preliminary efficacy, safety, and biomarker results in patients with previously treated metastatic ovarian cancer (OC) or non-small cell lung cancer (NSCLC) ASCO https://meetinglibrary.asco.org/record/188449/abstract
J. Silvio Gutkind, PhD – UC San Diego discusses Precision Medicine Identifies Key Recurring Mutation in Head and Neck Cancers AACR https://health.ucsd.edu/news/releases/Pages/2020-07-30-precision-medicine-identifies-key-recurring-mutation-in-head-and-neck-cancers.aspx
J. Silvio Gutkind, PhD – UC San Diego discusses Precision Medicine Identifies Key Recurring Mutation in Head and Neck Cancers AACR https://health.ucsd.edu/news/releases/Pages/2020-07-30-precision-medicine-identifies-key-recurring-mutation-in-head-and-neck-cancers.aspx
J. Silvio Gutkind, PhD – UC San Diego discusses Precision Medicine Identifies Key Recurring Mutation in Head and Neck Cancers AACR https://health.ucsd.edu/news/releases/Pages/2020-07-30-precision-medicine-identifies-key-recurring-mutation-in-head-and-neck-cancers.aspx
J. Silvio Gutkind, PhD – UC San Diego discusses Verastem Oncology Announces Presentation of Preclinical Data Supporting the Combination of VS-6766 and Defactinib in Metastatic Uveal Melanoma AACR https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-announces-presentation-preclinical-data-0 Â You may also be interested in: VS-6766 + Defactinib in Non-Small Cell Lung CancerÂ
J. Silvio Gutkind, PhD – UC San Diego discusses Verastem Oncology Announces Presentation of Preclinical Data Supporting the Combination of VS-6766 and Defactinib in Metastatic Uveal Melanoma AACR https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-announces-presentation-preclinical-data-0  You May Also Be Interested In: VS-6766 + Defactinib in Non-Small Cell Lung Cancer  Â
J. Silvio Gutkind, PhD – UC San Diego discusses Verastem Oncology Announces Presentation of Preclinical Data Supporting the Combination of VS-6766 and Defactinib in Metastatic Uveal Melanoma AACR https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-announces-presentation-preclinical-data-0
Guillermo Garcia-Manero, MD – MD Anderson Cancer Center discusses Astex Pharmaceuticals, Taiho Oncology, and Otsuka Pharmaceutical announce FDA and Health Canada approval of INQOVI® (decitabine and cedazuridine) tablets, oral hypomethylating agent (HMA) therapy for intermediate and high-risk MDS and CMML https://astx.com/astex-pharmaceuticals-taiho-oncology-and-otsuka-pharmaceutical-announce-fda-and-health-canada-approval-of-inqovi-decitabine-and-cedazuridine-tablets-oral-hypomethylating-agent-hma-therapy/
Guillermo Garcia-Manero, MD – MD Anderson Cancer Center discusses Astex Pharmaceuticals, Taiho Oncology, and Otsuka Pharmaceutical announce FDA and Health Canada approval of INQOVI® (decitabine and cedazuridine) tablets, oral hypomethylating agent (HMA) therapy for intermediate and high-risk MDS and CMML https://astx.com/astex-pharmaceuticals-taiho-oncology-and-otsuka-pharmaceutical-announce-fda-and-health-canada-approval-of-inqovi-decitabine-and-cedazuridine-tablets-oral-hypomethylating-agent-hma-therapy/
Guillermo Garcia-Manero, MD – MD Anderson Cancer Center discusses Astex Pharmaceuticals, Taiho Oncology, and Otsuka Pharmaceutical announce FDA and Health Canada approval of INQOVI® (decitabine and cedazuridine) tablets, oral hypomethylating agent (HMA) therapy for intermediate and high-risk MDS and CMML https://astx.com/astex-pharmaceuticals-taiho-oncology-and-otsuka-pharmaceutical-announce-fda-and-health-canada-approval-of-inqovi-decitabine-and-cedazuridine-tablets-oral-hypomethylating-agent-hma-therapy/
Mohamed Alaa Gouda, MD MD Anderson discusses Genomically informed longitudinal monitoring of circulating tumor DNA (ctDNA) to predict outcomes of cancer therapy ASCO2020 https://meetinglibrary.asco.org/record/188272/abstract
Mohamed Alaa Gouda, MD MD Anderson discusses Genomically informed longitudinal monitoring of circulating tumor DNA (ctDNA) to predict outcomes of cancer therapy ASCO2020 https://meetinglibrary.asco.org/record/188272/abstract
Quincy S. Chu, MD – University of Alberta discusses A phase Ib study of oral Chk1 inhibitor LY2880070 in combination with gemcitabine in patients with advanced or metastatic cancer ASCO https://meetinglibrary.asco.org/record/187856/abstract
Quincy S. Chu, MD – University of Alberta discusses A phase Ib study of oral Chk1 inhibitor LY2880070 in combination with gemcitabine in patients with advanced or metastatic cancer ASCO https://meetinglibrary.asco.org/record/187856/abstract
John Williams, Ph.D. – City of Hope discusses Antibody based redirection of meditope CAR-T cells selectively kill antigen bearing tumor cells  AACR https://vcusa.sparx-ip.net/aacr2020ep/?c=a&view=3&item=2020AB_6591
John Williams, Ph.D. – City of Hope discusses Antibody based redirection of meditope CAR-T cells selectively kill antigen bearing tumor cells  AACR  https://vcusa.sparx-ip.net/aacr2020ep/?c=a&view=3&item=2020AB_6591
John Williams, Ph.D. – City of Hope discusses Antibody based redirection of meditope CAR-T cells selectively kill antigen bearing tumor cells  AACR  https://vcusa.sparx-ip.net/aacr2020ep/?c=a&view=3&item=2020AB_6591
John Williams, Ph.D. – City of Hope discusses Antibody based redirection of meditope CAR-T cells selectively kill antigen bearing tumor cells  AACR  https://vcusa.sparx-ip.net/aacr2020ep/?c=a&view=3&item=2020AB_6591
Daniel Spakowicz, PhD – The James – Ohio State University Comprehensive Cancer Center discusses Microbiome Might Reveal Whether Immune Therapy Can Benefit a Patient, Study Shows   https://cancer.osu.edu/news/microbiome-might-reveal-whether-immune-therapy-can-benefit-a-patient-study-shows
Daniel Spakowicz, PhD – The James – Ohio State University Comprehensive Cancer Center discusses Microbiome Might Reveal Whether Immune Therapy Can Benefit a Patient, Study Shows https://cancer.osu.edu/news/microbiome-might-reveal-whether-immune-therapy-can-benefit-a-patient-study-shows
Daniel Spakowicz, PhD – The James – Ohio State University Comprehensive Cancer Center discusses Microbiome Might Reveal Whether Immune Therapy Can Benefit a Patient, Study Shows https://cancer.osu.edu/news/microbiome-might-reveal-whether-immune-therapy-can-benefit-a-patient-study-shows
Daniel Spakowicz, PhD – The James – Ohio State University Comprehensive Cancer Center discusses Microbiome Might Reveal Whether Immune Therapy Can Benefit a Patient, Study Shows https://cancer.osu.edu/news/microbiome-might-reveal-whether-immune-therapy-can-benefit-a-patient-study-shows
Erminia Massarelli, MD City of Hope discusses INDUCE-1: Report on safety run-in cohorts combining Inducible T-cell co-stimulatory receptor (ICOS) agonist GSK3359609 (GSK609) with platinum+5-FU chemotherapy (5-FU/plat), with or without pembrolizumab (PE), for the treatment of advanced solid tumors ASCO https://meetinglibrary.asco.org/record/184678/abstract
Erminia Massarelli, MD City of Hope discusses INDUCE-1: Report on safety run-in cohorts combining Inducible T-cell co-stimulatory receptor (ICOS) agonist GSK3359609 (GSK609) with platinum+5-FU chemotherapy (5-FU/plat), with or without pembrolizumab (PE), for the treatment of advanced solid tumors ASCO https://meetinglibrary.asco.org/record/184678/abstract
Erminia Massarelli, MD City of Hope discusses INDUCE-1: Report on safety run-in cohorts combining Inducible T-cell co-stimulatory receptor (ICOS) agonist GSK3359609 (GSK609) with platinum+5-FU chemotherapy (5-FU/plat), with or without pembrolizumab (PE), for the treatment of advanced solid tumorsASCOhttps://meetinglibrary.asco.org/record/184678/abstract
Michael Gerard McCusker, MD – University of Maryland Medical Systems discusses Cisplatin every three weeks versus weekly cisplatin or carboplatin with definitive radiotherapy for squamous cell carcinoma of the head and neck is associated with improved overall survival in a representative national population ASCO https://meetinglibrary.asco.org/record/184787/abstract
Michael Gerard McCusker, MD – University of Maryland Medical Systems discusses Cisplatin every three weeks versus weekly cisplatin or carboplatin with definitive radiotherapy for squamous cell carcinoma of the head and neck is associated with improved overall survival in a representative national population ASCO https://meetinglibrary.asco.org/record/184787/abstract
Michael Gerard McCusker, MD – University of Maryland Medical Systems discusses Cisplatin every three weeks versus weekly cisplatin or carboplatin with definitive radiotherapy for squamous cell carcinoma of the head and neck is associated with improved overall survival in a representative national population ASCO https://meetinglibrary.asco.org/record/184787/abstract
Rodney Paul Rocconi, MD University of South Alabama discusses A phase I combination study of GMCSF/bi-shRNA(furin) DNA-transfected autologous tumor immunotherapy and atezolizumab in recurrent/refractory advanced-stage ovarian cancer: Efficacy assessment in BRCA1/2-wt patientsASCOhttps://meetinglibrary.asco.org/record/185052/abstract
Rodney Paul Rocconi, MD University of South Alabama discusses A phase I combination study of GMCSF/bi-shRNA(furin) DNA-transfected autologous tumor immunotherapy and atezolizumab in recurrent/refractory advanced-stage ovarian cancer: Efficacy assessment in BRCA1/2-wt patients ASCO https://meetinglibrary.asco.org/record/185052/abstract
Rodney Paul Rocconi, MD University of South Alabama discusses A phase I combination study of GMCSF/bi-shRNA(furin) DNA-transfected autologous tumor immunotherapy and atezolizumab in recurrent/refractory advanced-stage ovarian cancer: Efficacy assessment in BRCA1/2-wt patients ASCO https://meetinglibrary.asco.org/record/185052/abstract
Shilpa Gupta, MD – Cleveland Clinic discusses Perioperative Novel Systemic Immunotherapy-Based Approaches in Urinary Cancers – Abstract 5019 and Abstract 5020
Shilpa Gupta, MD – Cleveland Clinic discusses Perioperative Novel Systemic Immunotherapy-Based Approaches in Urinary Cancers – Abstract 5019 and Abstract 5020
Miguel Garcia-Guzman, PH.D., Vice Chairman, Chief Scientific Officer, Rakuten Medical discusses Rakuten Medical Presents Data during AACR Characterizing how Illuminox Induces Cancer Cell Death and Enhances the Immune Response Preclinically Press Release https://www.prnewswire.com/news-releases/rakuten-medical-presents-data-characterizing-how-photoimmunotherapy-induces-cancer-cell-death-and-enhances-the-immune-response-preclinically-301080849.html
Miguel Garcia-Guzman, PH.D., Vice Chairman, Chief Scientific Officer, Rakuten Medical discusses Rakuten Medical Presents Data during AACR Characterizing how Illuminox Induces Cancer Cell Death and Enhances the Immune Response Preclinically Press Release https://www.prnewswire.com/news-releases/rakuten-medical-presents-data-characterizing-how-photoimmunotherapy-induces-cancer-cell-death-and-enhances-the-immune-response-preclinically-301080849.html
Miguel Garcia-Guzman, PH.D., Vice Chairman, Chief Scientific Officer, Rakuten Medical discusses Rakuten Medical Presents Data during AACR Characterizing how Illuminox Induces Cancer Cell Death and Enhances the Immune Response Preclinically Press Release https://www.prnewswire.com/news-releases/rakuten-medical-presents-data-characterizing-how-photoimmunotherapy-induces-cancer-cell-death-and-enhances-the-immune-response-preclinically-301080849.html
Miguel Garcia-Guzman, PH.D., Vice Chairman, Chief Scientific Officer, Rakuten Medical discusses Rakuten Medical Presents Data during AACR Characterizing how Illuminox Induces Cancer Cell Death and Enhances the Immune Response Preclinically Press Release https://www.prnewswire.com/news-releases/rakuten-medical-presents-data-characterizing-how-photoimmunotherapy-induces-cancer-cell-death-and-enhances-the-immune-response-preclinically-301080849.html
Anne Harris, MHP Childrens Minnesota discusses Juvenile granulosa cell tumor: An interim report from the international ovarian and testicular stromal tumor (OTST) registry ASCO https://meetinglibrary.asco.org/record/187770/abstract
Anne Harris, MHP Childrens Minnesota discusses Juvenile granulosa cell tumor: An interim report from the international ovarian and testicular stromal tumor (OTST) registry ASCO https://meetinglibrary.asco.org/record/187770/abstract
Anne Harris, MHP Childrens Minnesota discusses Juvenile granulosa cell tumor: An interim report from the international ovarian and testicular stromal tumor (OTST) registry ASCO https://meetinglibrary.asco.org/record/187770/abstract
Anne Harris, MHP Childrens Minnesota discusses Juvenile granulosa cell tumor: An interim report from the international ovarian and testicular stromal tumor (OTST) registry ASCO https://meetinglibrary.asco.org/record/187770/abstract
Anne Harris, MHP Childrens Minnesota discusses Juvenile granulosa cell tumor: An interim report from the international ovarian and testicular stromal tumor (OTST) registry ASCO https://meetinglibrary.asco.org/record/187770/abstract
Heather Losey, Ph.D., Director, Program Lead in Immuno-Oncology and Jared Lopes, Ph.D., Principal Scientist – Alkermes discusses New Preclinical Data on ALKS 4230 in Combination With Lucitanib to be Presented at 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II 2202 / 7 – The combination of a mouse ortholog of ALKS 4230, a selective agonist of the intermediate affinity IL-2 receptor, and the angiogenesis inhibitor lucitanib enhances antitumor activity
Heather Losey, Ph.D., Director, Program Lead in Immuno-Oncology and Jared Lopes, Ph.D., Principal Scientist – Alkermes discusses New Preclinical Data on ALKS 4230 in Combination With Lucitanib to be Presented at 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II 2202 / 7 – The combination of a mouse ortholog of ALKS 4230, a selective agonist of the intermediate affinity IL-2 receptor, and the angiogenesis inhibitor lucitanib enhances antitumor activity
Heather Losey, Ph.D., Director, Program Lead in Immuno-Oncology and Jared Lopes, Ph.D., Principal Scientist – Alkermes discusses New Preclinical Data on ALKS 4230 in Combination With Lucitanib to be Presented at 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II 2202 / 7 – The combination of a mouse ortholog of ALKS 4230, a selective agonist of the intermediate affinity IL-2 receptor, and the angiogenesis inhibitor lucitanib enhances antitumor activity
John Pagel, MD Swedish Cancer Institute discusses Adaptive Biotechnologies Receives Expanded FDA Clearance for the clonoSEQ® Assay to Assess Minimal Residual Disease (MRD) in Patients with Chronic Lymphocytic Leukemia https://www.globenewswire.com/news-release/2020/08/06/2074302/0/en/Adaptive-Biotechnologies-Receives-Expanded-FDA-Clearance-for-the-clonoSEQ-Assay-to-Assess-Minimal-Residual-Disease-MRD-in-Patients-with-Chronic-Lymphocytic-Leukemia.html
John Pagel, MD Swedish Cancer Institute discusses Adaptive Biotechnologies Receives Expanded FDA Clearance for the clonoSEQ® Assay to Assess Minimal Residual Disease (MRD) in Patients with Chronic Lymphocytic Leukemia https://www.globenewswire.com/news-release/2020/08/06/2074302/0/en/Adaptive-Biotechnologies-Receives-Expanded-FDA-Clearance-for-the-clonoSEQ-Assay-to-Assess-Minimal-Residual-Disease-MRD-in-Patients-with-Chronic-Lymphocytic-Leukemia.html